This latest announcement is the least exciting of coming developments imo and the study is also incomplete. The question still remains if stage 1&2 sensitivity in comparison to Roche is significantly better .I can’t see that that is clear in the latest announcement . I think that is what is to be established in the next round of testing ? I still strongly believe this is a buying opportunity.
Ann: Positive results for SubB2M Breast Cancer Test, page-25
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $59.09M | |||
| Open | High | Low | Value | Volume |
| 56.0¢ | 60.0¢ | 55.5¢ | $46.69K | 82.99K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3000 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 59.0¢ | 3797 | 2 |
View Market Depth
| Last trade - 11.37am 09/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |